Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. Verve is developing therapies to safely edit the genome of adults and confer lifelong protection from coronary artery disease, the most common form of heart disease and the leading cause of death worldwide. Founded by world-leading experts in cardiovascular medicine and gene editing, Verve is backed by a top-tier syndicate of investors, including GV (formerly Google Ventures), ARCH Venture Partners, F-Prime Capital, and Biomatics Capital. Verve is headquartered in Cambridge, Massachusetts, and has a research lab located at Pennovation Works, the University of Pennsylvania incubator space in Philadelphia.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/07/19 | $58,500,000 | Series A |
ARCH Venture Partners Biomatics Capital F-Prime Capital Partners GV  | undisclosed |
| 06/11/20 | $63,000,000 | Series A-2 |
ARCH Venture Partners Biomatics Capital Casdin Capital F-Prime Capital Partners GV Wellington Capital Management | undisclosed |
| 01/19/21 | $94,000,000 | Series B |
Biomatics Capital Casdin Capital Cormorant Asset Management GV Janus Henderson Investors Logos Capital Novo Holdings RA Capital Management Redmile Group Rock Springs Capital Surveyor Capital Wellington Capital Management | undisclosed |
